You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
亿胜生物科技(01061.HK)磋商乾眼症药物试验推进至下一阶段
阿思达克 07-19 12:13

亿胜生物科技(01061.HK)公布,诚如Mitotech所告知,有关共同开发滴眼液之第一阶段三期试验已於2019年6月成功完成,而公司全资附属EssexBio-Investment根据共同开发协议就第一阶段三期试验之实际出资总额约为1,611万美元。

第一阶段三期试验中已取得显示有关该产品功效及安全性之临床相关体徵及症状之正面顶线数据,该产品为含SkQ1之滴眼液,SkQ1作为其唯一活性药物成分,将提供为乾眼症领域之药品。第一阶段三期试验乃以约450名就诊患者为基础,彼等於约9周期间内接受治疗。

监於第一阶段三期试验中取得之正面试验数据,EssexBio-Investment与Mitotech正就将该产品之美国药监局三期临床试验推进至下一阶段(即第二阶段三期临床试验)进行讨论。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account